Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04534465 · ClinicalTrials.gov registry record · Phase 4
Study to Gather Information on the Acceptability of a New Flavor System With Increasing Levels of 2, 4, 6 g or Higher of Mannitol for PEG 3350 in Subjects Having Infrequent Bowel Movements.
A Phase 4 study of Constipation, sponsored by Bayer.
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04534465: Completed Phase 4 study of Constipation, sponsored by Bayer.
NCT04534465 is a Phase 4 study of Constipation that has completed, run by Bayer. The registered enrollment target is 50 participants, below the 204-participant average among 54 other Constipation trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04534465, a Phase 4 study of Constipation, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Study to gather information on the acceptability of a new flavor system with increasing levels of 2, 4, 6 g or higher of the sugar alcohol Mannitol for Polyethylene glycol (PEG) 3350 a drug stimulating bowel movement to pass stool in subjects having infrequent bowel movements. The taste of the various preparations will be measured by use of a rating scale.
Primary Outcome
Evaluated by 7-point scales: 1-extremely dislike, 2-moderately dislike, 3-dislike somewhat, 4-neither like nor dislike, 5-like somewhat, 6-moderately like, 7-extremely like
Conditions Studied
Interventions
- DRUG Polyethylene glycol (MiraLAX, BAY81-8430)
- DRUG Mannitol
Study Locations (1)
Tennessee
- Merck Consumer Center - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2013-02-13 |
| Est. Completion | 2013-03-19 |
| Phase | Phase 4 |
What the finished NCT04534465 record still lists
NCT04534465 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 204-participant average among 54 other Constipation trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Constipation appearing as the primary indexed condition, and to 2 interventions - of which Polyethylene glycol (MiraLAX, BAY81-8430) is the first listed.
NCT04534465 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT04534465 about?
NCT04534465 is a clinical study titled "Study to Gather Information on the Acceptability of a New Flavor System With Increasing Levels of 2, 4, 6 g or Higher of Mannitol for PEG 3350 in Subjects Having Infrequent Bowel Movements.". Study to gather information on the acceptability of a new flavor system with increasing levels of 2, 4, 6 g or higher of the sugar alcohol Mannitol for Polyethylene glycol (PEG) 3350 a drug stimulating bowel movement to pass stool in subjects having infrequent bowel movements. The taste of the vario...
What is the current status of trial NCT04534465?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2013-02-13. Estimated completion is 2013-03-19.
What conditions does trial NCT04534465 study?
This clinical trial studies the following conditions: Constipation.
What interventions are being tested in trial NCT04534465?
The interventions under investigation include: Polyethylene glycol (MiraLAX, BAY81-8430) (DRUG), Mannitol (DRUG).
Who is sponsoring clinical trial NCT04534465?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04534465 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Constipation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04534465's enrollment target sits among peer trials
50 34th of 54 higher than 19 of 54 other Constipation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Constipation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pre-operative Polyethylene Glycol 3350 for Minimally Invasive Urogynecologic Surgery
RECRUITING · Phase 4
-
Evaluation of Fecal Microbiome Changes After Antegrade Continence Enema Placement and Initiation of Bowel Flush Regimen
RECRUITING · Phase 4
-
Preop Laxatives in Robotic Urologic Surgery
RECRUITING · Phase 4
-
Extended Use of Polyethyleneglycol3350 Laxative in Constipated Patients
COMPLETED · Phase 4
-
An Open Label Study of Chronic Polyethyleneglycol3350 Use in Constipated Patients
COMPLETED · Phase 4
-
Comparison of PolyethyleneGlycol and Placebo for Relief of Constipation From Constipating Medications
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI